for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AbbVie Inc

ABBV.N

Latest Trade

86.56USD

Change

0.29(+0.34%)

Volume

114,814

Today's Range

86.54

 - 

86.79

52 Week Range

62.55

 - 

101.27

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
86.27
Open
86.59
Volume
114,814
3M AVG Volume
148.92
Today's High
86.79
Today's Low
86.54
52 Week High
101.27
52 Week Low
62.55
Shares Out (MIL)
1,764.83
Market Cap (MIL)
152,252.20
Forward P/E
8.26
Dividend (Yield %)
5.47

Next Event

Q3 2020 Abbvie Inc Earnings Release

Latest Developments

More

Abbvie Says Venclexta Receives FDA Full Approval For Acute Myeloid Leukemia

Allergan Aesthetics, An Abbvie Company, Acquires Innovative Luminera Dermal Filler Business

Allergan says Working Closely With Health Canada To Voluntarily Withdraw Fibristal Across Canada

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Industry

Biotechnology & Drugs

Contact Info

1 N Waukegan Rd

NORTH CHICAGO, IL

60064-1802

United States

+1.847.9327900

https://www.abbvie.com/

Executive Leadership

Richard A. Gonzalez

Chairman of the Board, Chief Executive Officer

Michael E. Severino

President, Vice Chairman

Carlos Alban

Vice Chairman, Chief Commercial Officer

Laura J. Schumacher

Vice Chairman, External Affairs and Chief Legal Officer

Robert A. Michael

Chief Financial Officer, Senior Vice President

Key Stats

2.00 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

28.2K

2018

32.7K

2019

33.3K

2020(E)

45.5K
EPS (USD)

2017

5.600

2018

7.910

2019

8.940

2020(E)

10.445
Price To Earnings (TTM)
18.98
Price To Sales (TTM)
4.20
Price To Book (MRQ)
10.35
Price To Cash Flow (TTM)
15.03
Total Debt To Equity (MRQ)
594.45
LT Debt To Equity (MRQ)
557.93
Return on Investment (TTM)
8.43
Return on Equity (TTM)
6.73

Latest News

Latest News

NIH tests therapies to help cut hospital stays for COVID-19 patients

The U.S. National Institutes of Health (NIH) has started a late-stage trial to evaluate if immune-modulating therapies from three drugmakers can help reduce the need for ventilators for COVID-19 patients and shorten their hospital stay.

NIH starts clinical trial testing antibody treatments in COVID-19 patients

The U.S. National Institutes of Health (NIH) said on Tuesday it has started a study to evaluate two antibody treatments in COVID-19 patients as part of the agency's program to identify promising drugs to help tackle the new coronavirus.

U.S. court voids $448 million award against AbbVie, but revives FTC claim over AndroGel

A federal appeals court on Wednesday threw out an order requiring AbbVie Inc <ABBV.N> and a partner to disgorge $448 million in profit for trying to keep generic versions of the blockbuster testosterone replacement drug AndroGel off the market.

AbbVie withdraws uterine fibroids drug from Canada

AbbVie Inc said on Wednesday it was voluntarily withdrawing its drug to treat noncancerous growths in the uterus from the Canadian market, following reports of severe liver injury.

US court voids $448 million award against AbbVie, AndroGel partner

A federal appeals court on Wednesday reversed an order that had required AbbVie Inc and a partner to disgorge $448 million in profit, in antitrust litigation brought by the U.S. Federal Trade Commission related to the testosterone replacement drug AndroGel.

BRIEF-I-Mab Says Abbvie Has A Right Of First Negotiation To In-License Further Development And Commercialization Of 2 Additional Lemzoparlimab-Based Bispecific Antibodies- Conf. Call

* SAYS POTENTIAL VALUE OF SUCH LICENSE OF THE 2 BISPECIFIC PROGRAMS IS A MINIMUM $1 BILLION IN UPFRONT AND MILESTONE PAYMENTS- CONF. CALL

AbbVie to develop and sell China-based I-Mab's cancer drug

U.S. drugmaker AbbVie Inc will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab's cancer drug, the companies said on Friday.

AbbVie to develop, sell I-Mab's lead cancer drug

Drugmaker AbbVie Inc has entered an agreement to develop and sell Chinese biotech company I-Mab's lead cancer drug, the companies said on Friday.

U.S. House Oversight Committee to subpoena AbbVie in drug-pricing probe

The U.S. House Oversight Committee on Tuesday decided to subpoena AbbVie Inc <ABBV.N> to seek documents on the drugmaker's blockbuster treatments, Humira and Imbruvica, as part of its investigation into drug-pricing practices.

U.S. House Oversight Committee to subpoena AbbVie in drug-pricing probe

The U.S. House Oversight Committee has decided to subpoena drugmaker Abbvie Inc to seek documents as part of its investigation into drug pricing practices.

AbbVie agrees to pay $24 million to resolve Humira California lawsuit

AbbVie Inc has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday.

AbbVie agrees to pay $24 mln to resolve Humira California lawsuit

AbbVie Inc has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday.

AbbVie's Humira powers profit beat as COVID-19 weighs on Botox sales

AbbVie Inc <ABBV.N> on Friday posted a quarterly adjusted profit above estimates as robust sales of its blockbuster arthritis treatment, Humira, helped cushion weak demand for its aesthetic drugs, including Botox, due to the COVID-19 pandemic.

BRIEF-Abbvie Says By June-End Total Business Recovered To More Than 90% Of Pre-COVID Levels - Conf Call

* ABBVIE SAYS BY THE END OF JUNE TOTAL BUSINESS RECOVERED TO MORE THAN 90% OF PRE-COVID LEVELS - CONF CALL

AbbVie reports loss as COVID-19 hits Botox sales

Drugmaker AbbVie Inc reported a loss in the second quarter on Friday, as comparable sales from wrinkle treatment Botox, acquired as part of its $63 billion Allergan Plc deal, slumped due to the impact of the COVID-19 pandemic.

Molecular Partners's AbbVie-partnered eye drug gets FDA safety snub

Swiss drugmaker Molecular Partners has suffered a setback after the U.S. Food and Drug Administration said the company's abicipar product for a blindness-causing eye disease had an unfavorable risk-benefit profile due to inflammation.

BRIEF-Allergan, An Abbvie Company, And Molecular Partners Receive CRL From FDA On Biologics License Application For Abicipar Pegol

* ALLERGAN, AN ABBVIE COMPANY, AND MOLECULAR PARTNERS RECEIVE COMPLETE RESPONSE LETTER FROM FDA ON BIOLOGICS LICENSE APPLICATION FOR ABICIPAR PEGOL

Sosei, AbbVie sign drug discovery deal worth up to $1 bln

Japan's Sosei Group Corp will collaborate with AbbVie Inc on a drug discovery partnership that could be worth up to $1 billion.

Japan's Sosei Group signs $377 mln drug discovery deal with Abbvie

Japan's Sosei Group Corp will collaborate with Abbvie Inc on drug discovery in a deal worth up to $377 million, the companies said on Thursday.

BRIEF-Sosei Group Corp - Sosei Heptares And Abbvie Announce New Discovery Collaboration Targeting Inflammatory Diseases

* SOSEI HEPTARES AND ABBVIE ANNOUNCE NEW DISCOVERY COLLABORATION TARGETING INFLAMMATORY DISEASES

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up